GB0317592D0 - Method - Google Patents

Method

Info

Publication number
GB0317592D0
GB0317592D0 GBGB0317592.4A GB0317592A GB0317592D0 GB 0317592 D0 GB0317592 D0 GB 0317592D0 GB 0317592 A GB0317592 A GB 0317592A GB 0317592 D0 GB0317592 D0 GB 0317592D0
Authority
GB
United Kingdom
Prior art keywords
oatp
polymorphisms
pharmacokinetics
relates
statin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0317592.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to GBGB0317592.4A priority Critical patent/GB0317592D0/en
Publication of GB0317592D0 publication Critical patent/GB0317592D0/en
Priority to PCT/GB2004/003236 priority patent/WO2005012566A2/en
Priority to DK04743565T priority patent/DK1651774T3/da
Priority to US10/566,054 priority patent/US7700277B2/en
Priority to EP04743565A priority patent/EP1651774B1/en
Priority to PL04743565T priority patent/PL1651774T3/pl
Priority to AT04743565T priority patent/ATE373730T1/de
Priority to DE602004009083T priority patent/DE602004009083T2/de
Priority to ES04743565T priority patent/ES2291899T3/es
Priority to SI200430494T priority patent/SI1651774T1/sl
Priority to JP2006521655A priority patent/JP4166257B2/ja
Priority to PT04743565T priority patent/PT1651774E/pt
Priority to CY20071101470T priority patent/CY1107801T1/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Semiconductor Lasers (AREA)
GBGB0317592.4A 2003-07-26 2003-07-26 Method Ceased GB0317592D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB0317592.4A GB0317592D0 (en) 2003-07-26 2003-07-26 Method
PT04743565T PT1651774E (pt) 2003-07-26 2004-07-26 Utilização de polimorfismos na oatp-c humana, associados com um efeito sobre a farmacocinética da estatina, em humanos em terapia com estatina
AT04743565T ATE373730T1 (de) 2003-07-26 2004-07-26 Verwendung von humanen oatp-c polymorphismen, die einen effekt auf die pharmakokinetik von statin haben, bei der statin-therapie
DK04743565T DK1651774T3 (da) 2003-07-26 2004-07-26 Anvendelse af polymorfier i humant OATP-C forbundet med en virkning på statinfarmakinetik i mennesker under statinterapi
US10/566,054 US7700277B2 (en) 2003-07-26 2004-07-26 Use of polymorphisms in human OATP-C associated with an effect on statin pharmacokinetics in humans in statin therapy
EP04743565A EP1651774B1 (en) 2003-07-26 2004-07-26 Use of polymorphisms in human oatp-c associated with an effect on statin pharmacokinetics in humans in statin therapy
PL04743565T PL1651774T3 (pl) 2003-07-26 2004-07-26 Zastosowanie palimorfizmów ludzkiego OATP-C związanych z wpływem na farmakokinetykę statyn u ludzi leczonych statynami
PCT/GB2004/003236 WO2005012566A2 (en) 2003-07-26 2004-07-26 Use of polymorphisis in human oatp-c associated with an effect on statin pharmacokinetics in humans in statin therapy
DE602004009083T DE602004009083T2 (de) 2003-07-26 2004-07-26 Verwendung von humanen oatp-c polymorphismen, die einen effekt auf die pharmakokinetik von statin haben, bei der statin-therapie
ES04743565T ES2291899T3 (es) 2003-07-26 2004-07-26 Uso de polmorfismos en oatp-c humano asociados con un efecto sobre la farmacocinetica de la estatina en seres humanos en terapia que usa estatina.
SI200430494T SI1651774T1 (sl) 2003-07-26 2004-07-26 Uporaba polimorfizmov v cloveskem OATP-C, povezanih z ucinkom na farmakokinetiko statina pri ljudehs statinsko terapijo
JP2006521655A JP4166257B2 (ja) 2003-07-26 2004-07-26 ヒトにおけるスタチン薬物動態に対する効果と関連するヒトoatp−cにおける多型のスタチン療法での使用
CY20071101470T CY1107801T1 (el) 2003-07-26 2007-11-14 Χρηση πολυμορφισμων στον ανθρωπινο oatp-c που σχετιζονται με μια επιδραση στη φαρμακοκινητικη στατινης σε ανθρωπους σε θεραπεια στατινης

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0317592.4A GB0317592D0 (en) 2003-07-26 2003-07-26 Method

Publications (1)

Publication Number Publication Date
GB0317592D0 true GB0317592D0 (en) 2003-08-27

Family

ID=27772801

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0317592.4A Ceased GB0317592D0 (en) 2003-07-26 2003-07-26 Method

Country Status (12)

Country Link
US (1) US7700277B2 (cg-RX-API-DMAC7.html)
EP (1) EP1651774B1 (cg-RX-API-DMAC7.html)
JP (1) JP4166257B2 (cg-RX-API-DMAC7.html)
AT (1) ATE373730T1 (cg-RX-API-DMAC7.html)
CY (1) CY1107801T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004009083T2 (cg-RX-API-DMAC7.html)
DK (1) DK1651774T3 (cg-RX-API-DMAC7.html)
ES (1) ES2291899T3 (cg-RX-API-DMAC7.html)
GB (1) GB0317592D0 (cg-RX-API-DMAC7.html)
PL (1) PL1651774T3 (cg-RX-API-DMAC7.html)
PT (1) PT1651774E (cg-RX-API-DMAC7.html)
WO (1) WO2005012566A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006008656A2 (en) * 2004-07-21 2006-01-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Oatp-c gene c463a polymorphism underlies variable response of statin therapy
WO2009106838A1 (en) * 2008-02-29 2009-09-03 Isis Innovation Limited Diagnostic methods
US9817001B2 (en) 2008-05-27 2017-11-14 Boston Heart Diagnostics Corporation Methods for determining LDL cholesterol treatment
US8470541B1 (en) 2008-09-27 2013-06-25 Boston Heart Diagnostics Corporation Methods for separation and immuno-detection of biomolecules, and apparatus related thereto
CA2851838A1 (en) 2011-10-13 2013-04-18 Boston Heart Diagnostics Corporation Compositions and methods for treating and preventing coronary heart disease
US9828624B2 (en) 2013-07-24 2017-11-28 Boston Heart Diagnostics Corporation Driving patient compliance with therapy
CA2968221A1 (en) 2014-11-17 2016-05-26 Boston Heart Diagnostic Corporation Cardiovascular disease risk assessment
US10572811B2 (en) * 2015-01-29 2020-02-25 Splunk Inc. Methods and systems for determining probabilities of occurrence for events and determining anomalous events
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN110904215A (zh) * 2019-12-16 2020-03-24 西安和合医学检验所有限公司 用于同步检测slco1b1基因的两个snp位点的基因多态性的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US32011A (en) * 1861-04-09 Coffee-pot
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
GB8902689D0 (en) 1989-02-07 1989-03-30 Ici Plc Assay method
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
EP0728218B1 (en) 1993-11-12 2008-01-02 PHRI Properties, Inc. Hybridization probes for nucleic acid detection, universal stems, methods and kits
WO2000008157A2 (en) 1998-08-07 2000-02-17 Axys Pharmaceuticals, Inc. Human anion transporter genes atnov
US20020090622A1 (en) * 2000-08-23 2002-07-11 Monisola Adeokun Chemical compounds

Also Published As

Publication number Publication date
DE602004009083D1 (de) 2007-10-31
WO2005012566A2 (en) 2005-02-10
CY1107801T1 (el) 2013-06-19
WO2005012566A3 (en) 2005-06-16
JP4166257B2 (ja) 2008-10-15
ATE373730T1 (de) 2007-10-15
JP2007500005A (ja) 2007-01-11
DK1651774T3 (da) 2008-01-07
DE602004009083T2 (de) 2008-06-19
US20070031838A1 (en) 2007-02-08
PL1651774T3 (pl) 2007-12-31
EP1651774B1 (en) 2007-09-19
US7700277B2 (en) 2010-04-20
EP1651774A2 (en) 2006-05-03
PT1651774E (pt) 2007-11-16
ES2291899T3 (es) 2008-03-01

Similar Documents

Publication Publication Date Title
CY1107801T1 (el) Χρηση πολυμορφισμων στον ανθρωπινο oatp-c που σχετιζονται με μια επιδραση στη φαρμακοκινητικη στατινης σε ανθρωπους σε θεραπεια στατινης
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
WO2004103960A3 (en) Compounds and uses thereof
WO2004034990A3 (en) Methods and compositions for use in treating cancer
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2004004644A3 (en) Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
WO2004030625A3 (en) Synergistic methods and compositions for treating cancer
WO2003068310A3 (en) Method for the prevention and treatment
EP1515724A4 (en) MITOTIC KINESINE HEMMER
ATE428411T1 (de) Hdl-verstärkende kombinationstherapie-komplexe
WO2005016883A3 (en) Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
WO2003101444A8 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
CY1111565T1 (el) Θεραπεια συνδυασμου του zd6474 με 5-fu και/ή cpt-11
TW200518769A (en) Use of calcitonin in osteoarthritis
NO20040516L (no) Kombinasjonsterapi for behandling av kreft.
WO2006002437A3 (en) Treatment of conditions involving demyelination
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
WO2004033666A3 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
WO2005013911A3 (en) Protective and therapeutic uses for tocotrienols
SE0301654D0 (sv) Novel compounds
NO20053903D0 (no) Nukleotidlipidesterderivater.
WO2005011611A3 (en) Bicyclic compounds and compositions as pdf inhibitors
UA85187C2 (en) 2-aminobenzoyl derivatives
IL181713A0 (en) Use of il-17f for the treatment and/or prevention of neurological diseases
WO2005056054A3 (en) METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)